カテゴリ： GlobalData, アメリカ, 企業調査

Amgen Inc (AMGN)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Amgen Inc (AMGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011413
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月22日
◆ページ数：94
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc (AMGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amgen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Amgen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Amgen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Amgen Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Amgen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Amgen Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Gamida Cell Raises US$10 Million In Series E Financing 12
Partnerships 14
Biocartis Enters into Co-Development Agreement with Amgen 14
Adaptive Biotechnologies Enters into Agreement with Amgen for Multiple Myeloma 15
Adaptive Biotech Enters into Agreement with Amgen 16
Biocartis Partners with Amgen 17
Exosome Diagnostics Enters into Agreement with Amgen 18
Flatiron Health Partners with Amgen 19
Biocartis Enters into Agreement with Amgen 20
Dako Enters into Co-Development Agreement with Amgen for Companion Diagnostic 21
Dako Enters Into Co-Development Agreement With Amgen For Molecular Diagnostic Test 22
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 23
KineMed Enters Into Co-Development Agreement With Amgen For Kinetic Biomarkers Of Brain Proteinopathies 24
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 25
Dako Enters Into Co-Development Agreement With Amgen 26
Dako Enters Into Co-Development Agreement With Amgen 27
Warnex Medical Labs Enters Into Distribution Agreement With deCODE genetics 28
Merger 29
AstraZeneca Rumored To Merge With Amgen 29
Amgen Enters into Licensing Agreement with Unilife 30
Atara Biotherapeutics Enters Into Licensing Agreement with Amgen 31
Debt Offering 32
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 32
Unilife Raises USD30 Million in First Tranche of Private Placement of 6% Senior Secured Convertible Notes Due 2023 34
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 36
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 38
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 40
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 42
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 44
Acquisition 46
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 46
Amgen Inc – Key Competitors 48
Amgen Inc – Key Employees 49
Amgen Inc – Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Joint Venture 57
Recent Developments 58
Strategy And Business Planning 58
Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 58
Financial Announcements 59
Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 59
Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 61
Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 63
Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 66
Oct 27, 2016: Amgen Reports Third Quarter 2016 Financial Results 69
Jul 27, 2016: Amgen Reports Second Quarter 2016 Financial Results 72
Apr 28, 2016: Amgen’s First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90 75
Jan 28, 2016: Amgen’s 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share Increased 19 Percent To $10.38 77
Corporate Communications 79
Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires 79
Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 80
Sep 22, 2017: Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 81
Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 82
Nov 02, 2016: Amgen Appoints Lori Johnston As Senior Vice President, Human Resources 83
Oct 14, 2016: Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors 84
Jun 17, 2016: Amgen Appoints Esteban Santos Executive Vice President, Operations 85
Legal and Regulatory 86
Jul 20, 2016: Amgen Announces Settlement Of Securities Litigation 86
Government and Public Interest 87
Jul 11, 2017: Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket 87
Product News 88
Oct 17, 2016: West to Showcase Expertise in Injectable Drug Containment and Delivery at PDA Universe of Pre-filled Syringes & Injection Devices 88
Other Significant Developments 90
Sep 25, 2017: Amgen Provides Update On Hurricane Maria 90
Mar 29, 2017: Amgen Enters into Agreement with Inovalon and Avalere to Engage Value-based Contracting Opportunities 91
Jan 09, 2017: DaVita Enters Into New Sourcing and Supply Agreement with Amgen and Initiates 2017 Kidney Care Guidance 92
Feb 12, 2016: West’s Daikyo Crystal Zenith Cyclic Olefin Polymer Selected by Amgen 93
Appendix 94
Methodology 94
About GlobalData 94
Contact Us 94
Disclaimer 94

List of Tables
Amgen Inc, Medical Equipment, Key Facts, 2016 2
Amgen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Amgen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Amgen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Amgen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Amgen Inc, Deals By Market, 2011 to YTD 2017 9
Amgen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Gamida Cell Raises US$10 Million In Series E Financing 12
Biocartis Enters into Co-Development Agreement with Amgen 14
Adaptive Biotechnologies Enters into Agreement with Amgen for Multiple Myeloma 15
Adaptive Biotech Enters into Agreement with Amgen 16
Biocartis Partners with Amgen 17
Exosome Diagnostics Enters into Agreement with Amgen 18
Flatiron Health Partners with Amgen 19
Biocartis Enters into Agreement with Amgen 20
Dako Enters into Co-Development Agreement with Amgen for Companion Diagnostic 21
Dako Enters Into Co-Development Agreement With Amgen For Molecular Diagnostic Test 22
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 23
KineMed Enters Into Co-Development Agreement With Amgen For Kinetic Biomarkers Of Brain Proteinopathies 24
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 25
Dako Enters Into Co-Development Agreement With Amgen 26
Dako Enters Into Co-Development Agreement With Amgen 27
Warnex Medical Labs Enters Into Distribution Agreement With deCODE genetics 28
AstraZeneca Rumored To Merge With Amgen 29
Amgen Enters into Licensing Agreement with Unilife 30
Atara Biotherapeutics Enters Into Licensing Agreement with Amgen 31
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 32
Unilife Raises USD30 Million in First Tranche of Private Placement of 6% Senior Secured Convertible Notes Due 2023 34
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 36
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 38
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 40
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 42
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 44
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 46
Amgen Inc, Key Competitors 48
Amgen Inc, Key Employees 49
Amgen Inc, Other Locations 51
Amgen Inc, Subsidiaries 53
Amgen Inc, Joint Venture 57

★海外企業調査レポート[Amgen Inc (AMGN)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Pentair plc：企業の戦略・SWOT・財務情報
    Pentair plc - Strategy, SWOT and Corporate Finance Report Summary Pentair plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Globo Comunicacao e Participacoes S.A.：企業の戦略的SWOT分析
    Globo Comunicacao e Participacoes S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Rhizen Pharmaceuticals SA-製薬・医療分野：企業M&A・提携分析
    Summary Rhizen Pharmaceuticals SA (Rhizen Pharma), a subsidiary of Alembic Pharmaceuticals Ltd is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products includes c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 ag …
  • Astron Corp Ltd (ATR)：企業の財務・戦略的SWOT分析
    Astron Corp Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • WebMD Health Corp：企業の戦略的SWOT分析
    WebMD Health Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ORBCOMM Inc (ORBC)：企業の財務・戦略的SWOT分析
    ORBCOMM Inc (ORBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Symphony Ltd：企業の戦略・SWOT・財務情報
    Symphony Ltd - Strategy, SWOT and Corporate Finance Report Summary Symphony Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Games Workshop Group PLC (GAW)：企業の財務・戦略的SWOT分析
    Summary Games Workshop Group PLC (Games Workshop) is a miniature wargaming products manufacturing company. The company designs, manufactures and distributes fantasy miniatures, metal soldiers and rule books. Its products include warhammer age of sigmar, warhammer 40000, the hobbit, scenery, painting …
  • TES Aviation Group：企業の戦略・SWOT・財務情報
    TES Aviation Group - Strategy, SWOT and Corporate Finance Report Summary TES Aviation Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Tribune Media Company：企業の戦略・SWOT・財務分析
    Tribune Media Company - Strategy, SWOT and Corporate Finance Report Summary Tribune Media Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • IDT Biologika GmbH-製薬・医療分野：企業M&A・提携分析
    Summary IDT Biologika GmbH (IDT Biologika), a subsidiary of Klocke Pharma-Service GmbH, is a manufacturer of vaccines and bio-pharmaceuticals products. It offers services which include integrated development and manufacturing services in four major areas of animal health, vaccines, pharmaceuticals a …
  • Nexif Energy Management Pte Ltd：電力：M&Aディール及び事業提携情報
    Summary Nexif Energy Management Pte Ltd (Nexif Energy) a subsidiary of Nexif Pte Ltd invests in power projects in partnership with Denham Capital. The company carries out the development and management of power and infrastructure projects in South Asia and South East Asia. It develops and manages po …
  • Abivax SA (ABVX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce f …
  • RPM International Inc：戦略・SWOT・企業財務分析
    RPM International Inc - Strategy, SWOT and Corporate Finance Report Summary RPM International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Allergy Therapeutics Plc (AGY)：製薬・医療：M&Aディール及び事業提携情報
    Summary Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alter …
  • VIA Technologies, Inc (2388)：企業の財務・戦略的SWOT分析
    VIA Technologies, Inc (2388) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Golden Gate Capital：企業の戦略的SWOT分析
    Golden Gate Capital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • MYnd Analytics Inc (MYAN)-医療機器分野：企業M&A・提携分析
    Summary MYnd Analytics Inc (MYnd), formerly CNS Response Inc is a biotechnology company that offers medication development programs. The company performs analysis and research, and develops medication for individual patients suffering from mental health and other issues. It provides an PEER Online, …
  • Oklahoma Medical Research Foundation：製薬・医療：M&Aディール及び事業提携情報
    Summary Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute. The institute conducts disease research for human diseases such as lupus, alzheimer’s and diseases of aging, diabetics, cancer, children’s disease, autoimmune disease and heart diseases. Its portfolio …
  • LOT Polish Airlines SA：企業の戦略・SWOT・財務分析
    LOT Polish Airlines SA - Strategy, SWOT and Corporate Finance Report Summary LOT Polish Airlines SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆